Asahi Kasei company Zoll has signed an with BrainCool for the BrainCool System/IQool System and the IQool System Pads in the US and major European markets.
The companies also plan to work together to expand distribution to selected Asian markets.
The agreement broadens Zoll’s range of temperature management solutions, encompassing both intravascular technology and surface options.
Branded as the IQool System in the US, the BrainCool System is an advanced surface temperature management system with gel-free and adhesive-free pads.
This system is intended to maintain fever control and manage patient temperature in critical care settings.
The IQool System has programmable protocol settings and acute temperature control, as well as an advanced user interface.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataZoll Circulation president Christopher Barnabas said: 鈥淓xpanding Zoll鈥檚 temperature management offering to include a high-quality surface option supports our mission to improve patient outcomes and help save lives.
鈥淲ith our Thermogard XPand Thermogard HQ products – the world鈥檚 only intravascular temperature management technology – and BrainCool鈥檚 IQool System, we now offer a unique combination of solutions that deliver high-quality patient care while recognising hospitals’ evolving protocols and increased nursing workload.鈥�
In May this year, Zoll secured approval from the US Food and Drug Administration for its remed膿 system for conditional use with magnetic resonance imaging.
The implantable transvenous phrenic nerve stimulator is intended for treating patients who experience moderate to severe central sleep apnea.
